## **CANACCORD** Genuity

To us there are no foreign markets.™

## **Starpharma Holdings Limited**

Biotechnology

#### **Australian Equity Research**

16 November 2015

<b>BUY</b> unchanged	
PRICE TARGET unchanged	A\$1.12
Price (16-Nov) Ticker	A\$0.91 SPL-ASX

52-Week Range	(A\$):		0.4	11 - 0.85
Avg Daily Vol (OC	389.6			
Market Cap (A\$	292 320.5			
Shares Out. (M)				
Enterprise Value	266 26.1 (6.2)			
Last Cash Balan				
Last Quarter Cas				
Major Sharehold	Allan Gray			
			M&G Inve	stments
			Acori	n Capital
			Dow C	Chemical
FYE Jun	2015A	2016E	2017E	2018E
Sales (A\$M)	0.8	3.6	8.6	24.6
PBT (A\$M)	(19.0)	(12.4)↓	(2.1)↓	18.0↓
Previous	(19.0)	(7.9)	(0.2)	20.7
Net Income (A\$M)	(19.0)	(12.4)↓	(2.1)↓	18.0↓
Previous	(19.0)	(7.9)	(0.2)	20.7
EPS (AUc)	(5.91)个	(3.88)↓	(0.66)↓	5.63↓
Previous	(5.94)	(2.49)	(0.08)	6.48
Cash Position (A\$M)	30.8	18.4	16.3	34.3
0.9				



SPL is developing new pharmaceutical, agrochemical and industrial products based on its proprietary dendrimer polymer technology. Matthijs Smith | Canaccord Genuity (Australia) Ltd. | matthijs.smith@canaccord.com.au | +61.3.8688.9107

### **Company Update**

# Impressive preclinical data from targeted cancer drug

SPL has released impressive pre-clinical data from a targeted cancer drug that uses one of SPL's proprietary dendrimer polymers to link a toxic cancer drug with an antibody that specifically binds to cancer cells. In a mouse model of human cancer, SPL's targeted drug construct showed significantly greater cancer-killing activity than either the targeting antibody on its own or the marketed, targeted drug, Kadcyla. While experimental observations in animal models are often not replicated in human patients, in this case, the significantly improved activity compared with established human therapeutics (Herceptin and Kadcyla) is very encouraging. Furthermore, these data suggest that SPL's dendrimer polymers may provide useful scaffolds for building a number of targeted drug conjugates. We maintain our BUY recommendation for SPL with a A\$1.12 price target based on a 12-year discounted cash flow (13.4% discount rate, no terminal value).

#### High anti-tumour activity of targeted DEP conjugate (TDC) significant.

This study compared the anti-tumour activity of SPL's TDC (which uses the antibody Herceptin as a targeting agent), Roche's Kadcyla (an antibody drug conjugate (ADC) that combines Herceptin with a cytotoxic drug called DM1), and the therapeutic antibody Herceptin, against human tumour tissue that had be implanted in mice. Three, weekly doses of SPL's TDC resulted in significant reduction of the implanted tumour tissue which was maintained for over 60 days during which time all of the mice remained alive. In contrast, tumour tissue in mice treated with Kadcyla and Herceptin grew five-fold over 40 days and, by 50 days, all of the mice in these arms of the study had ceased to be.

#### Targeted drugs considered the 'golden bullet' for cancer therapy

The challenge with all cancer therapies is that the types of drugs that kill cancer cells are usually also toxic to healthy cells. Even when drugs are directed at specific areas of cancer cell biology, such as their higher frequency of cell division, administration of cancer drugs still often results in some collateral damage. The identification of antibodies that bind to proteins primarily found only on cancer has opened up the possibility of highly targeted approaches whereby the toxic cancer drugs are specifically delivered to cancer cells. Kadcyla and Adcetris are two of the more successful such targeted antibody drug conjugates (ADCs) which, according to SPL, generated over US \$1B in combined sales in 2014.

#### Potential to attract strong commercial interest

The robust anti-tumour activity of SPL's TDC compared with established ADC, is likely to attract commercial interest from pharma companies on its own. However, we believe the real value of these data will come from the potential to use dendrimer polymer scaffolds as the foundation for a range of TDCs. The regular structure of dendrimer polymers has a number of advantages in terms of manufacturing, consistency and amount of payload that can be loaded and delivered. With such promising data coming from initial animal studies, we expect a number of pharma and biotech companies will have an interest in accessing SPL's dendrimers to develop new, targeted cancer therapeutics.

Canaccord Genuity is the global capital markets group of Canaccord Genuity Group Inc. (CF : TSX | CF. : LSE)

The recommendations and opinions expressed in this research report accurately reflect the research analyst's personal, independent and objective views about any and all the companies and securities that are the subject of this report discussed herein.

#### FINANCIAL SUMMARY

Financial Performance										
Year End	June	2014A	2015A	2016F	2017F	2018F	2019F	2020F	2021F	2022F
	<b>A</b> 14		0.0	07			47			40.0
VivaGel Condoms royalty	\$M \$M	-	0.3	0.7	1.4	2.4	4.7	6.8 14.1	9.6	12.6 58.4
BV prevention royalty Drug delivery royalty	\$M	-	-	-	-	3.4	6.9	14.1	28.7 5.6	11.3
Agrochemicals royalty	\$M	-	-	-	1.5	3.8	7.5	11.3	13.5	11.3
Milestone payments	\$M			2.9	5.7	15.0	35.0	35.0	75.0	50.0
Other	\$M	0.3	0.6	2.9	5.7	- 15.0			75.0	
Total product revenues	\$M	0.3	0.8	3.6	8.6	24.6	54.1	67.2	132.4	147.2
		-	-	-	-	-	-	-	-	-
Interest revenue Grants and tax rebates	\$M \$M	1.0 4.7	0.9 0.0	0.5 3.9	0.8 4.0	1.5 3.2	1.8 2.9	1.8 0.9	1.8 0.7	1.8 0.5
Total revenue	\$M	6.0	1.7	<u> </u>	13.4	29.2	58.8	69.8	134.9	149.4
Total levelide	ψivi	-	-		- 13.4	- 25.2			- 104.5	
R&D expenses	\$M	-11.0	-16.3	-16.0	-11.0	-6.5	-2.0	-1.5	-1.0	-0.5
Administration expenses	\$M	-4.9	-4.4	-4.4	-4.5	-4.7	-4.9	-5.0	-5.2	-5.4
Other expenses	\$M	-	-0.0	-	-	-	-	-	-	-
Total expenses	\$M	-15.9	-20.6	-20.4	-15.5	-11.2	-6.9	-6.5	-6.2	-5.9
Net profit before tax	\$M	-9.9	-19.0	-12.4	-2.1	18.0	51.9	63.3	128.6	143.5
Tax expense	\$M	-	-		-	-	-	- -1.2	- -38.6	-43.0
Net profit after tax	\$M	-9.9	-19.0	-12.4	-2.1	18.0	51.9	62.1	<u>90.1</u>	100.4
EPS (cps)	cps	-3.1	-5.9	-3.9	-0.7	5.6	16.2	19.4	28.1	31.3
Balance Sheet										
Year End	June	2014A	2015A	2016F	2017F	2018F	2019F	2020F	2021F	2022F
Cash and cash equivalents	\$M	24.0	30.8	18.4	16.3	34.3	45.2	45.2	45.2	45.2
Other current assets	\$M	4.6	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
Non-current assets	\$M	8.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3	9.3
Total assets	\$M	36.9	44.4	31.9	29.8	47.9	58.7	58.7	58.7	58.7
Current borrowings	\$M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other current liabilities	\$M	3.8	6.7	6.7	6.7	6.7	6.7	6.7	6.7	6.7
Non-current borrowings	\$M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other non-current liabilities	\$M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Totals liabilities	\$M	3.9	6.8	6.8	6.8	6.8	6.8	6.8	6.8	6.8
National	\$M	33.0	37.6	25.1	23.0	41.0	51.9	51.9	51.9	54.0
Net assets	φIVI	33.0	37.0	23.1	23.0	41.0	51.9	51.9	51.9	51.9
Contributed equity	\$M	140.3	160.9	160.9	160.9	160.9	160.9	160.9	160.9	160.9
Reserves	\$M	4.9	7.9	7.9	7.9	7.9	7.9	7.9	7.9	7.9
Retained profit/ losses	\$M	-112.3	-131.2	-143.6	-145.8	-127.7	-116.8	-116.8	-116.8	-116.8
Total equity	\$M	33.0	37.6	25.1	23.0	41.0	51.9	51.9	51.9	51.9
Cash Flow										
Cash Flow Year End	June	2014A	2015A	2016F	2017F	2018F	2019F	2020F	2021F	2022F
Year End										
Year End Cash received from products & service	\$M	0.4	0.5	3.6	8.6	24.6	54.1	67.2	132.4	147.2
Year End Cash received from products & service Payments to suppliers	\$M \$M	0.4 -16.1	0.5 -19.3	3.6 -20.4	8.6 -15.5	24.6 -11.2	54.1 -6.9	67.2 -6.5	132.4 -6.2	147.2 -5.9
Year End Cash received from products & service Payments to suppliers Net interest	\$M \$M \$M	0.4 -16.1 1.2	0.5 -19.3 1.0	3.6 -20.4 0.5	8.6 -15.5 0.8	24.6 -11.2 1.5	54.1 -6.9 1.8	67.2 -6.5 1.8	132.4 -6.2 1.8	147.2 -5.9 1.8
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates	\$M \$M \$M \$M	0.4 -16.1	0.5 -19.3	3.6 -20.4	8.6 -15.5	24.6 -11.2	54.1 -6.9	67.2 -6.5 1.8 0.9	132.4 -6.2 1.8 0.7	147.2 -5.9 1.8 0.5
Year End Cash received from products & service Payments to suppliers Net interest	\$M \$M \$M	0.4 -16.1 1.2	0.5 -19.3 1.0	3.6 -20.4 0.5	8.6 -15.5 0.8 4.0	24.6 -11.2 1.5 3.2	54.1 -6.9 1.8 2.9	67.2 -6.5 1.8	132.4 -6.2 1.8	147.2 -5.9 1.8
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations	\$M \$M \$M \$M \$M <b>\$M</b>	0.4 -16.1 1.2 4.7 - <b>-9.8</b>	0.5 -19.3 1.0 4.2 - - <b>13.6</b>	3.6 -20.4 0.5 3.9 - - - <b>12.4</b>	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - <b>18.0</b>	54.1 -6.9 1.8 2.9 - <b>51.9</b>	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b>	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax	\$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7	0.5 -19.3 1.0 4.2	3.6 -20.4 0.5 3.9 -	8.6 -15.5 0.8 4.0	24.6 -11.2 1.5 3.2	54.1 -6.9 1.8 2.9 -	67.2 -6.5 1.8 0.9 -1.2	132.4 -6.2 1.8 0.7 -38.6	147.2 -5.9 1.8 0.5 -43.0
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities	\$M \$M \$M \$M <b>\$M</b> <b>\$M</b>	0.4 -16.1 1.2 4.7 -9.8 -0.3	0.5 -19.3 1.0 4.2 - - <b>13.6</b>	3.6 -20.4 0.5 3.9 - - - <b>12.4</b>	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - <b>18.0</b>	54.1 -6.9 1.8 2.9 - <b>51.9</b>	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b>	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations	\$M \$M \$M \$M \$M <b>\$M</b>	0.4 -16.1 1.2 4.7 - <b>-9.8</b>	0.5 -19.3 1.0 4.2 - -13.6 -0.7	3.6 -20.4 0.5 3.9 - - - <b>12.4</b>	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - <b>18.0</b>	54.1 -6.9 1.8 2.9 - <b>51.9</b>	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b>	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares	\$M \$M \$M \$M <b>\$M</b> <b>\$M</b> \$M	0.4 -16.1 1.2 4.7 -9.8 -0.3	0.5 -19.3 1.0 4.2 - -13.6 -0.7	3.6 -20.4 0.5 3.9 - - - <b>12.4</b>	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - <b>18.0</b>	54.1 -6.9 1.8 2.9 - <b>51.9</b>	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b>	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing	\$M \$M \$M \$M \$M <b>\$M</b> \$M \$M	0.4 -16.1 1.2 4.7 -9.8 -0.3	0.5 -19.3 1.0 4.2 - -13.6 -0.7	3.6 -20.4 0.5 3.9 - - - <b>12.4</b>	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - <b>18.0</b>	54.1 -6.9 1.8 2.9 - 51.9 -	67.2 -6.5 1.8 0.9 -1.2 62.1	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b> - - - - - - - - - - - - - - - - - - -
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid	\$M \$M \$M \$M <b>\$M</b> \$ <b>M</b> \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - -	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5	3.6 -20.4 0.5 3.9 - 12.4	8.6 -15.5 0.8 4.0 - - <b>2.1</b>	24.6 -11.2 1.5 3.2 - - - - - - -	54.1 -6.9 1.8 2.9 - 51.9 -	67.2 -6.5 1.8 0.9 -1.2 62.1	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b>	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b>
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows	\$M \$M \$M <b>\$M</b> <b>\$M</b> \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 -9.8 -0.3 0.2 - -0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - -0.0	3.6 -20.4 0.5 3.9 - - - 12.4 - - - - - - - - -	8.6 -15.5 0.8 4.0 - 	24.6 -11.2 1.5 3.2 - - - - - - - -	54.1 -6.9 1.8 2.9 - 51.9 - - -41.0	67.2 -6.5 1.8 0.9 -1.2 62.1 - -62.1	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b> -  -90.1	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b> - - - - - - - - - - - - - - - - - - -
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities	\$M \$M \$M \$M \$ <b>M</b> \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - -0.0 0.2	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 -0.0 20.5	3.6 -20.4 0.5 3.9 - -12.4	8.6 -15.5 0.8 4.0 - <b>2.1</b> - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - 51.9 - - - 41.0 - 41.0	67.2 -6.5 1.8 0.9 -1.2 62.1 - -62.1	132.4 -6.2 1.8 0.7 -38.6 <b>90.1</b> -  -90.1	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b> - - - - - - - - - - - - - - - - - - -
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities Net increase / decrease in cash	\$M \$M \$M \$M \$ <b>M</b> \$ <b>M</b> \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - - -0.3 - - - - - - 0.2 - - - 0.2 - - - 0.2 - - - 9.9	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 - -0.0 20.5 - -0.0 20.5	3.6 -20.4 0.5 3.9 - -12.4	8.6 -15.5 0.8 4.0 - 	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - 51.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b> -62.1 -62.1 -62.1	132.4 -6.2 1.8 0.7 -38.6 90.1 - - -90.1 - - -90.1 - - - -90.1	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b> - -100.4 - - <b>100.4</b>
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities Net increase / decrease in cash Cash at beginning of the year	\$M \$M \$M \$M \$ <b>M</b> \$ <b>M</b> \$M \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 -9.8 -0.3 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.2 -9.9 -3.3.8	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - -0.0 20.5 6.2 24.0	3.6 -20.4 0.5 3.9 - -12.4	8.6 -15.5 0.8 4.0 - 	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - 51.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 <b>62.1</b> -62.1 -62.1 -62.1	132.4 -6.2 1.8 0.7 -38.6 90.1 - - -90.1 - - -90.1 - - - -90.1	147.2 -5.9 1.8 0.5 -43.0 <b>100.4</b> - -100.4 - - <b>100.4</b>
Year End         Cash received from products & service         Payments to suppliers         Net interest         Grants and rebates         Net tax         Cash from operations         Cash from investing activities         Net cash from issue of shares         Net cash from borrowing         Dividends paid         Other financing cash flows         Cash from financing activities         Net increase / decrease in cash         Cash at beginning of the year         Exchange rates         Cash at end of year	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - -12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities Net increase / decrease in cash Cash at beginning of the year Exchange rates Cash at end of year Valuation	\$M \$M \$M \$M \$ <b>M</b> \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 -12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities Net increase / decrease in cash Cash at beginning of the year Exchange rates Cash at end of year Valuation Risk free rate	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - - 12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 1.8 0.5 -43.0 100.4 - -100.4 - -100.4 - -100.4 - -100.4 - -100.4
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash at beginning of the year Exchange rates Cash at end of year Valuation Risk free rate Market premium	\$M \$M \$M \$M <b>\$M</b> <b>\$M</b> \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 -12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 1.8 0.5 -43.0 100.4 - -100.4 - -100.4 - -100.4 - -100.4 - -100.4
Year End         Cash received from products & service         Payments to suppliers         Net interest         Grants and rebates         Net itax         Cash from operations         Cash from investing activities         Net cash from issue of shares         Net cash from borrowing         Dividends paid         Other financing activities         Net increase / decrease in cash         Cash at beginning of the year         Exchange rates         Cash at end of year         Valuation         Risk free rate         Market premium         Beta	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - 12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End Cash received from products & service Payments to suppliers Net interest Grants and rebates Net tax Cash from operations Cash from investing activities Net cash from issue of shares Net cash from borrowing Dividends paid Other financing cash flows Cash from financing activities Net increase / decrease in cash Cash at beginning of the year Exchange rates Cash at end of year Valuation Risk free rate Market premium Beta Discount rate	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - 12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End         Cash received from products & service         Payments to suppliers         Net interest         Grants and rebates         Net itax         Cash from operations         Cash from investing activities         Net cash from issue of shares         Net cash from borrowing         Dividends paid         Other financing activities         Net increase / decrease in cash         Cash at beginning of the year         Exchange rates         Cash at end of year         Valuation         Risk free rate         Market premium         Beta	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - <b>12.4</b> - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End         Cash received from products & service         Payments to suppliers         Net interest         Grants and rebates         Net tax         Cash from operations         Cash from investing activities         Net cash from issue of shares         Net cash from borrowing         Dividends paid         Other financing cash flows         Cash from financing activities         Net increase / decrease in cash         Cash at beginning of the year         Exchange rates         Cash at end of year         Valuation         Beta         Discount rate         Forecast period         12-month price target	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$M \$	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - 12.4 - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 
Year End         Cash received from products & service         Payments to suppliers         Net interest         Grants and rebates         Net interest         Grants and rebates         Net tax         Cash from operations         Cash from investing activities         Net cash from issue of shares         Net cash from borrowing         Dividends paid         Other financing activities         Cash from financing activities         Net increase / decrease in cash         Cash at end of year         Valuation         Risk free rate         Market premium         Beta         Discount rate         Forecast period	\$M \$M \$M \$M \$M \$M \$M \$M \$M \$M	0.4 -16.1 1.2 4.7 - -9.8 - -0.3 0.2 - - - 0.0 0.2 - - - 0.0 - 0.2 - - 3.8 0.0	0.5 -19.3 1.0 4.2 -13.6 -0.7 20.5 - - -0.0 20.5 6.2 24.0 0.6	3.6 -20.4 0.5 3.9 - <b>12.4</b> - - - - - - - - - - - - - - - - - - -	8.6 -15.5 0.8 4.0 -2.1 - - - - - - - - - - - - - - - - - - -	24.6 -11.2 1.5 3.2 - - - - - - - - - - - - - - - - - - -	54.1 -6.9 1.8 2.9 - - - - - - - - - - - - - - - - - - -	67.2 -6.5 1.8 0.9 -1.2 62.1 - - -62.1 - - -62.1 - - - - - - - - - - - - - - - - - - -	132.4 -6.2 1.8 0.7 -38.6 90.1 - - - -90.1 - - - - - - - - - - - - - - - - - - -	147.2 -5.9 -43.0 100.4 - 

SOURCE: Company reports and Canaccord Genuity estimates

## Appendix: Important Disclosures

#### **Analyst Certification**

Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.

Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### Target Price / Valuation Methodology:

Starpharma Holdings Limited - SPL

Our price target is based on a 12-year discounted cash flow valuation (13.4% WACC, 1.6 beta, no TGR) of risk-adjusted royalty and milestone payments that SPL may receive from products developed using its proprietary dendrimer polymer technology.

#### Risks to achieving Target Price / Valuation:

Starpharma Holdings Limited - SPL

A significant proportion of our valuation is based on commercial development of VivaGel which is currently in Phase-3 clinical trials for the treatment of bacterial vaginosis. If these trial fail to achieve a clinically meaningful benefit, it will have a significant impact on our valuation. Similarly, the value of the dendrimer formulation technology requires those products to successfully complete several clinical trials and secure regulatory approvals. Finally, the commercial development of most of SPL product is based on current and future partnerships. If the company is unable to secure these, or they are secured on financial terms different to what we have forecast, or the partner does not effectively proceed with commercialising SPL's products, it will impact on the valuation of SPL.

#### **Distribution of Ratings:**

#### Global Stock Ratings (as of 11/16/15)

Rating	Coverag	Coverage Universe		
	#	%	%	
Buy	581	61.03%	32.36%	
Hold	282	29.62%	12.41%	
Sell	30	3.15%	6.67%	
Speculative Buy	59	6.20%	59.32%	
	952*	100.0%		

\*Total includes stocks that are Under Review

#### **Canaccord Genuity Ratings System**

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.

HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.

**SELL**: The stock is expected to generate negative risk-adjusted returns during the next 12 months.

**NOT RATED:** Canaccord Genuity does not provide research coverage of the relevant issuer.

"Risk-adjusted return" refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.


#### **Risk Qualifier**

**SPECULATIVE**: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

#### Canaccord Genuity Company-Specific Disclosures (as of date of this publication)

Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Corporate Finance/ Investment Banking services from Starpharma Holdings Limited in the next six months.

The primary analyst, a member of primary analyst's household, or any individual directly involved in the preparation of this research, has a long position in the shares or derivatives, or has any other financial interest in Starpharma Holdings Limited, the value of which increases as the value of the underlying equity increases.



#### **Online Disclosures**

Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@canaccordgenuity.com. The reader may also obtain a copy of Canaccord Genuity's policies and procedures regarding the dissemination of research by following the steps outlined above.

#### **General Disclosures**

"Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity Inc., Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 50%-owned by Canaccord Genuity Group Inc.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity Inc., a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne.

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Corporate Finance/Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance/Investment Banking activities, or to recommendations contained in the research.

Canaccord Genuity and its affiliated companies may have a Corporate Finance/Investment Banking or other relationship with the issuer that is the subject of this research and may trade in any of the designated investments mentioned herein either for their own account or the accounts of their customers, in good faith or in the normal course of market making. Accordingly, Canaccord Genuity or their affiliated companies, principals or employees (other than the authoring analyst(s) who prepared this research) may at any time have a long or short position in any such designated investments, related designated investments or in options, futures or other derivative instruments based thereon.

Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity's policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity's policy is available upon request.

The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity's judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

Canaccord Genuity's salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research.

Canaccord Genuity's affiliates, principal trading desk, and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

#### For Canadian Residents:

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

#### For United States Residents:

Canaccord Genuity Inc., a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Inc. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### For United Kingdom and European Residents:

This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

#### For Jersey, Guernsey and Isle of Man Residents:

This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

#### For Australian Residents:

This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited. Canaccord Genuity Wealth Management is a division of Canaccord Genuity (Australia) Limited.

#### For Singapore Residents:

This research is distributed pursuant to 32C of the Financial Advisers under an arrangement between each of the Canaccord Genuity entities that publish research and Canaccord Genuity Singapore Pte. Ltd who is an exempt financial adviser under section 23(1)(d) of the Financial Advisers Act. This research is only intended for persons who fall within the definition of accredited investor, expert investor or institutional investor as defined under section 4A of the Securities and Futures Act. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity Singapore Pte. Ltd. (Contact Tel: +65 6854 6150) in respect of any matters arising from, or in connection with, the research.

#### For Hong Kong Residents:

This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

#### Additional information is available on request.

Copyright © Canaccord Genuity Corp. 2015 . - Member IIROC/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited 2015. - Member LSE, authorized and regulated by the Financial Conduct Authority.

Copyright © Canaccord Genuity Inc. 2015 . - Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited 2015 . – Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and regulated by ASIC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity Inc or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.